<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> (<z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A) at 7 to 16 mg/kg/day was administered for eight to 18 months to four patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease with bilateral <z:hpo ids='HP_0012121'>panuveitis</z:hpo> resistant to the combination of <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="23359">colchicine</z:chebi>, and <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Visual acuity was maintained or improved in <z:hpo ids='HP_0000001'>all</z:hpo> eyes </plain></SENT>
<SENT sid="2" pm="."><plain>Color vision also improved significantly </plain></SENT>
<SENT sid="3" pm="."><plain>A dramatic and significant decrease of the <z:hpo ids='HP_0011010'>chronic</z:hpo> vitreous haze occurred within the first two weeks of therapy and persisted until the end of the study </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="46" ids="15035">Retinal</z:chebi> <z:mp ids='MP_0001845'>inflammation</z:mp>, including <z:mp ids='MP_0001914'>hemorrhages</z:mp>, exudates, <z:hpo ids='HP_0000969'>edema</z:hpo>, and fluorangiographic abnormalities, decreased progressively in <z:hpo ids='HP_0000001'>all</z:hpo> eyes </plain></SENT>
<SENT sid="5" pm="."><plain>The severity of the anterior and posterior <z:hpo ids='HP_0011009'>acute</z:hpo> attacks also decreased significantly </plain></SENT>
<SENT sid="6" pm="."><plain>This study suggests that <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> is beneficial for the treatment of refractory and severe <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, but its side effects require careful follow-up </plain></SENT>
</text></document>